Lead sponsor
Chengdu Brilliant Pharmaceutical Co., Ltd.
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
1
Trials led
0
Ongoing
478
Total enrollment
0
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 3
1
Trials by status
Unknown
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 DiabetesBMI 18.5-35Ph 3Unknown478